Matching Placebo (Remternetug) Clinical Trials (2026): 5 Studies for Alzheimer's Disease & Alzheimers Disease
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 Matching Placebo (Remternetug) clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Alzheimer's Disease & Alzheimers Disease) and 3,699 total planned enrollment. 2 Phase 3 Matching Placebo (Remternetug) trials are listed. 2 Matching Placebo (Remternetug) clinical trials are actively recruiting at 24 U.S. sites across 12 states. Most recent activity: NCT06647498 (Aug 2034).
Where to Participate: All Matching Placebo (Remternetug) Trial Sites in the U.S. (24 sites across 12 states)
Every actively recruiting Matching Placebo (Remternetug)trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University of Alabama in Birmingham | Birmingham35294 | NCT05552157 | Map |
| AL | University of Alabama in Birmingham | Birmingham35294 | NCT06647498 | Map |
| CA | University of California San Diego Medical Center | La Jolla92037 | NCT05552157 | Map |
| CA | University of California San Diego Medical Center | La Jolla92037 | NCT06647498 | Map |
| CT | Yale University School of Medicine | New Haven06510 | NCT05552157 | Map |
| CT | Yale University School of Medicine | New Haven06510 | NCT06647498 | Map |
| GA | Emory University | Atlanta30329 | NCT05552157 | Map |
| GA | Emory University | Atlanta30329 | NCT06647498 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT05552157 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT06647498 | Map |
| IN | Indiana University School of Medicine | Indianapolis46202 | NCT05552157 | Map |
| IN | Indiana University School of Medicine | Indianapolis46202 | NCT06647498 | Map |
| MO | Washington University in St. Louis | St Louis63110 | NCT05552157 | Map |
| MO | Washington University in St. Louis | St Louis63110 | NCT06647498 | Map |
| NY | New York University Medical Center | New York10016 | NCT05552157 | Map |
| NY | New York University Medical Center | New York10016 | NCT06647498 | Map |
| PA | University of Pittsburgh | Pittsburgh15213 | NCT05552157 | Map |
| PA | University of Pittsburgh | Pittsburgh15213 | NCT06647498 | Map |
| RI | Butler Hospital | Providence02096 | NCT05552157 | Map |
| RI | Butler Hospital | Providence02096 | NCT06647498 | Map |
| TX | Kerwin Research and Memory Center | Dallas75231 | NCT05552157 | Map |
| TX | Kerwin Research and Memory Center | Dallas75231 | NCT06647498 | Map |
| WA | University of Washington | Seattle98195 | NCT05552157 | Map |
| WA | University of Washington | Seattle98195 | NCT06647498 | Map |
Matching Placebo (Remternetug) clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P2/P3 | 2 | 2 | ||
| P3 | 1 | 1 | 2 |
Recruiting Matching Placebo (Remternetug) clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06647498 | DIAN-TU-002A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | P2/P3 | Alzheimers Disease | 280 | Nov 2024 |
| NCT05552157 | DIAN-TUA Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | P2/P3 | Alzheimers Disease | 280 | Nov 2024 |
Matching Placebo (Remternetug) clinical trials by indication
Alzheimers Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06647498 | DIAN-TU-002 | P2/P3 | recruiting | A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation |
| NCT05552157 | DIAN-TU | P2/P3 | recruiting | A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation |
Alzheimer's Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06653153 | LY3372993 | P3 | active not recruiting | A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) |
| NCT05463731 | LY3372993 | P3 | completed | A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07056309 | LY3372993 | P1 | completed | A Study of Remternetug (LY3372993) in Healthy Participants |
Matching Placebo (Remternetug) pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| LY3372993 | NCT06653153 | P3 | active not recruiting | Alzheimer's Disease | 1,400 | — |
| LY3372993 | NCT05463731 | P3 | completed | Alzheimer's Disease | 1,667 | — |
All Matching Placebo (Remternetug) trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06647498 | DIAN-TU-002 | A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | P2/P3 | recruiting | 280 | Washington University School of Medicine | Nov 2024 |
| NCT05552157 | DIAN-TU | A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation | P2/P3 | recruiting | 280 | Washington University School of Medicine | Nov 2024 |
| NCT06653153 | LY3372993 | A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) | P3 | active not recruiting | 1,400 | Eli Lilly and Company | Oct 2024 |
| NCT05463731 | LY3372993 | A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) | P3 | completed | 1,667 | Eli Lilly and Company | Aug 2022 |
| NCT07056309 | LY3372993 | A Study of Remternetug (LY3372993) in Healthy Participants | P1 | completed | 72 | Eli Lilly and Company | Jun 2025 |
Matching Placebo (Remternetug) clinical trials: frequently asked questions
- How many Matching Placebo (Remternetug) clinical trials are there?
- 5 Matching Placebo (Remternetug) clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 2 are marked completed.
- Are Matching Placebo (Remternetug) clinical trials recruiting in 2026?
- Yes — 2 Matching Placebo (Remternetug) trials are actively recruiting in 2026, with 24 U.S. sites across 12 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Matching Placebo (Remternetug) being studied for?
- Matching Placebo (Remternetug) is being studied for Alzheimer's Disease, Alzheimers Disease, Alzheimers Disease, Familial, Dementia, Healthy. The trials are grouped by indication on this page.
- What phase is Matching Placebo (Remternetug) in?
- Matching Placebo (Remternetug) clinical trials span 2 Phase 3, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Matching Placebo (Remternetug) clinical trials?
- The lead sponsor across the most Matching Placebo (Remternetug) trials is Eli Lilly and Company, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Matching Placebo (Remternetug)as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: